Shanghai Biopharma Output Climbs 15% To Over RMB 200 Billion
This article was originally published in PharmAsia News
Executive Summary
Shanghai’s biopharma industry grew over 15% annually to exceed RMB 200 billion ($32 billion) in the three years from 2009 to 2012 as clinical trial approvals and new companies sprouted.